Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$12.8M
Filings
171
Firms Hired
4
Active Period
2001–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 946
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 946
Maintaining Investments in New Innovation Act
2025 · second_quarter · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.1672
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.946
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
Client expense: — · Firm income: $80,000
Matched citations: S.864
Maintaining Investments in New Innovation Act
2025 · second_quarter · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.1672
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.946
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
Client expense: — · Firm income: $80,000
Matched citations: S.864
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 946
Maintaining Investments in New Innovation Act
2025 · first_quarter · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.1672
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.946
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
Client expense: — · Firm income: $80,000
Matched citations: S.864
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to H.R 5539/S. 3131 - the ORPHAN Cures Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R 5539
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to H.R 5539/S. 3131 - the ORPHAN Cures Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 3131
Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 946
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit and issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to H.R./S.3131 - the ORPHAN Cures Act.
Client expense: — · Firm income: $50,000
Matched citations: S.3131
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.5539
Maintaining Investments in New Innovation Act
2024 · fourth_quarter · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.5547
340B Program. Home Infusion for Part B Products. H.R.830 - HELP Copays Act. Medicare Reimbursement for New Technologies.
Client expense: — · Firm income: $80,000
Matched citations: H.R.830
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: S.3131
Maintaining Investments in New Innovation Act
2024 · fourth_quarter · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: S.476
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.5539
Maintaining Investments in New Innovation Act
2024 · third_quarter · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.5547
340B. Home Infusion for Part B Products. H.R.830 - HELP Copays Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.830
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: S.3131
Source: Senate LDA